The effect of gender on the clinical outcome of PD-1/PD-L1 inhibitor in advanced lung cancer patients

ABSTRACT:

Background:

Programmed death protein-1/ligand-1 (PD-1/L1) inhibitors have widely used in the treatment of lung cancer. Some literatures indicated that different gender might not have equal immune response, but no agreement have reached on the issue. Hence, we performed a systematic review and meta-analysis that examine the effect of gender on the clinical outcome of PD-1/PD-L1 inhibitor in advanced lung cancer patients.

Methods:

Related database and conferences were searched. Studies that reported the relationship between gender and the overall survival (OS) or progression-free survival (PFS) of PD-1/L1 inhibitor were included. Meta-analysis was conducted to obtain pooled hazard ratios (HRs) with 95% CI.

Results:

We included 34 studies with 11,883 lung cancer pat

SUBMITTER: Wu B 

PROVIDER: S-EPMC10470728 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature